Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Poznansky, Ph.D., M.B.,Ch.B.

Co-Author

This page shows the publications co-authored by Mark Poznansky and Patrick Reeves.
Connection Strength

6.153
  1. Reeves PM, Raju Paul S, Baeten L, Korek SE, Yi Y, Hess J, Sobell D, Scholzen A, Garritsen A, De Groot AS, Moise L, Brauns T, Bowen R, Sluder AE, Poznansky MC. Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling. Sci Rep. 2020 08 07; 10(1):13311.
    View in: PubMed
    Score: 0.980
  2. Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC. Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. Oncotarget. 2018 07 13; 9(54):30472.
    View in: PubMed
    Score: 0.849
  3. Reeves PM, Sluder AE, Paul SR, Scholzen A, Kashiwagi S, Poznansky MC. Application and utility of mass cytometry in vaccine development. FASEB J. 2018 01; 32(1):5-15.
    View in: PubMed
    Score: 0.809
  4. Reeves PM, Abbaslou MA, Kools FRW, Vutipongsatorn K, Tong X, Gavegnano C, Schinazi RF, Poznansky MC. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. Oncotarget. 2017 11 07; 8(55):94040-94053.
    View in: PubMed
    Score: 0.805
  5. Reeves PM, Abbaslou MA, Kools FRW, Poznansky MC. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth. Anticancer Drugs. 2017 10; 28(9):935-942.
    View in: PubMed
    Score: 0.804
  6. Reeves PM, Paul SR, Sluder AE, Brauns TA, Poznansky MC. Q-vaxcelerate: A distributed development approach for a new Coxiella burnetii vaccine. Hum Vaccin Immunother. 2017 12 02; 13(12):2977-2981.
    View in: PubMed
    Score: 0.803
  7. Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J. 2020 05; 34(5):6027-6037.
    View in: PubMed
    Score: 0.240
  8. Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, Liu Q, Callahan MV, Sluder AE, Gelfand JA, Chen H, Poznansky MC. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019 05; 33(5):6596-6608.
    View in: PubMed
    Score: 0.222
  9. Scholzen A, Richard G, Moise L, Baeten LA, Reeves PM, Martin WD, Brauns TA, Boyle CM, Raju Paul S, Bucala R, Bowen RA, Garritsen A, De Groot AS, Sluder AE, Poznansky MC. Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine. Front Immunol. 2019; 10:207.
    View in: PubMed
    Score: 0.221
  10. Li B, Zeng Y, Reeves PM, Ran C, Liu Q, Qu X, Liang Y, Liu Z, Yuan J, Leblanc PR, Ye Z, Sluder AE, Gelfand JA, Brauns TA, Chen H, Poznansky MC. AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression. Cancer Immunol Res. 2018 05; 6(5):539-551.
    View in: PubMed
    Score: 0.207
  11. Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, Chen H, Orsulic S, Brauns T, Leblanc P, Scholler N, Dranoff G, Gelfand J, Poznansky MC. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol. 2014 Feb 24; 7:15.
    View in: PubMed
    Score: 0.157
  12. Scholzen A, Richard G, Moise L, Hartman E, Bleeker-Rovers CP, Reeves PM, Raju Paul S, Martin WD, De Groot AS, Poznansky MC, Sluder AE, Garritsen A. Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever. Infect Immun. 2019 10; 87(10).
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.